Immunolight, LLC Announces Expansion of its Phase 1 Trial to All Solid Tumor Types

Immunolight LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, is excited to announce that its X-PACT 101 Phase 1 Clinical Trial is now open to patients with all Solid Tumors types. The phase 1 study of its X-Ray Activation of Psoralen Cancer Treatment system (X-PACT) in Breast, Melanoma, Sarcoma, and Head and Neck Cancers has now been expanded to include patients with any type of Solid Tumor. Reach out to Immunolight on its social media (LinkedIn, Facebook; and Instagram), or through the Immunolight website immunolight.com for more information about how to navigate participation in this clinical trial!

The Immunolight X-PACT system uses a combination of 8-MOP a plant derived molecule (also known as 8-methoxypsoralen or methoxsalen) and the innovative Immunolight energy converting (EC) materials that convert deeply penetrating energies, such as low dose X-ray, into UV light inside solid tumors in the body. The (EC) materials and 8-MOP are co-injected into a solid tumor, and low dose x-ray energy is applied at the site making it a targeted treatment. The EC materials convert the applied x-ray into UV light which activates the 8-MOP inside the solid tumor to kill cancerous cells.

Specific details about the updated Phase 1 trial eligibility criteria and trial locations can be found on the ClinicalTrials.gov website: https://clinicaltrials.gov/ct2/show/NCT04389281

“This expansion of our Phase I trial to include all solid tumor types will open up our trial to many more patients, which has been our top priority from the beginning,” Immunolight founder and CEO Rick Bourke said.

President Harold Walder commented, "We are thrilled to open up our Phase I trial to a greater patient population, and use our paradigm changing cancer treatment to treat solid tumors of any origin."

Recruiting Patients for Phase 1 Trial of the X-PACT System in Certain Solid Tumors

Immunolight LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, announced today it is now recruiting patients for a Phase 1 study of its X-PACT Cancer Treatment system in advanced in Breast, Melanoma, Sarcoma, and Head and Neck Cancers.

The heart of the X-PACT system is 8-MOP (also known as 8-methoxypsoralen or methoxsalen) which has been successfully used for decades in the treatment of autoimmune disease, skin disorders and certain skin and blood cancers. However, since UV light, which is needed to activate 8-MOP, cannot penetrate through tissue, it has not been possible to use 8-MOP to treat solid tumors.  Immunolight's X-PACT system solves this problem.  Innovative Immunolight phosphor materials convert tissue penetrating energies, such as low dose X-ray, into UV light inside solid tumors in the body.  These energy converting phosphors are injected along with 8-MOP into the solid tumor, and low dose x-ray energy is applied at the site.  The phosphors convert the x-ray into UV light which activates the 8-MOP inside the solid tumor to kill the cancer.

More details about the Phase 1 trial and eligibility criteria can be found at https://clinicaltrials.gov/ct2/show/NCT04389281. 

Immunolight founder and CEO Rick Bourke commented, "We are thrilled to start patient recruitment and begin this Phase 1 trial, bringing our innovative technology to fruition in treating cancer and starting what we believe is a new era in cancer treatment."

This milestone is the culmination of over 13 years of intense research and development in partnership with Duke University and Duke Medical Center where a team of over 30 scientists, physicians and engineers has been active.  "From day one, our highest priority has been to translate this amazing science into a paradigm changing cancer treatment in patients," President Harold Walder said. "We are so excited to take this next step to get the treatment into the clinic."

FDA Clearance to Initiate Phase 1 Trial of the X-PACT System in Solid Tumors

DURHAM, North Carolina, August 31, 2021 — Immunolight, LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, announced today it has received FDA clearance to enter phase 1 study in patients with breast, melanoma, sarcoma and head and neck cancers.

The heart of the X-PACT (X-ray Psoralen Activated Cancer Treatment) system is psoralen, a naturally occurring compound which has been successfully used for decades in the treatment of autoimmune disease, skin disorders and certain skin and blood cancers. It has not, however, been able to be used to treat solid tumors due to the fact that UV light, which is needed to activate psoralen, cannot penetrate through tissue to reach the solid tumors. Immunolight has now made that possible.

Immunolight innovated materials that convert tissue penetrating energies, such as low dose X-ray, into UV light inside a solid tumor in the body. The energy converting materials are injected along with psoralen inside the solid tumor, then low dose x-ray energy is applied at the site. The energy converting materials convert the x-ray into UV light which activates the psoralen inside the solid tumor to kill the cancer.

“Transitioning into a clinical stage company represents a significant milestone in the company’s history and the potential beginning of a new era in cancer treatment,” says Immunolight founder and CEO, Rick Bourke.

Currently in its 15th year of multidisciplinary research and development activities, Immunolight developed X-PACT in partnership with Duke University and Duke Medical Center with a team of over 30 scientists, physicians and engineers. “Our highest priority has been to translate this amazing science into a paradigm-changing cancer treatment in patients,” Immunolight President Harold Walder says. “We are so excited to get this treatment into the clinic and potentially change patient’s lives and transform their treatment outcomes.”

X-PACT Paper Wins SEAAPM 2017 Best Paper Award

Durham, North Carolina, April 4, 2017 – The South Eastern Chapter of the American Association of Physicists in Medicine (SEAAPM) has chosen Immunolight’s paper, X-Ray Psoralen Activated Cancer Therapy to receive it’s 2017’s best paper award.

Immunolight LLC is a biomedical firm leading the way in technologies that transform energy sources. Immunolight technology has the potential to create a dramatic shift in the treatment of cancer. It wasn’t that long ago that the treatments were limited to three options that included chemotherapy, radiation and surgery.

Although there have been improvements in all three areas, cancer, which has devastating effects emotionally, physically and financially, continues to be one of the most grueling diseases that affect us today.

X-PACT, X-ray Psoralen Activated Cancer Therapy is a new approach in the treatment of solid cancer tumors that utilizes psoralen, a potent, natural compound found in foods like celery, figs and citrus fruits. When exposed to UV light, psoralen causes cell death in cancer cells with the potential to induce an immune response against cancer from inside the tumor.

With a team of over thirty scientists, physicians and engineers, led by President Harold Walder, Immunolight is creating a paradigm shift in the treatment of cancer.

Best Paper Award

SEAAPM is a chapter of the American Association of Physicists in Medicine (AAPM), which is the leading organization in medical physics. Founded in 1958, the American Association of Physicists in Medicine (AAPM) promotes the application of physics to medicine and biology, to encourage interest and training as well as to prepare and distribute technical information in medical physics and related fields.

The SEAAPM region includes, North and South Carolina, Alabama, Mississippi, Georgia and Tennessee, with twenty-one regional AAPM Chapters.

The SEAAPM best paper award is open to papers authored by active SEAAPM members.
Nominations are put forth by active chapter members and then voted on by an awards committee.

“Publishing the results of our development activities is an important part of the technology development. We are honored to be presented with the SEAAPM 2017 Best Paper Award.” Immunolight President Harold Walder said.